Compare RNAC & ISPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNAC | ISPR |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 175.8M |
| IPO Year | 2016 | 2023 |
| Metric | RNAC | ISPR |
|---|---|---|
| Price | $6.41 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $38.80 | $7.50 |
| AVG Volume (30 Days) | ★ 92.7K | 67.8K |
| Earning Date | 03-12-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,091,000.00 | ★ $96,965,571.00 |
| Revenue This Year | N/A | $11.60 |
| Revenue Next Year | N/A | $40.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $1.44 |
| 52 Week High | $20.00 | $4.98 |
| Indicator | RNAC | ISPR |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 52.77 |
| Support Level | $6.23 | $2.98 |
| Resistance Level | $6.60 | $3.68 |
| Average True Range (ATR) | 0.43 | 0.33 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 16.02 | 35.26 |
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.